RJA
VNRX icon

Raymond James & Associates’s VolitionRx Ltd VNRX Stock Holding History

Raymond James & Associates’s Portfolio VNRX Stock Details VNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,556
Closed -$118K – 4222
2021
Q1 		$118K Buy
1,556
+861
+124% +$73.9K ﹤0.01% 3748
2020
Q4 		$54K Buy
+695
New +$47.8K ﹤0.01% 3619

Other funds holding VNRX

LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's VNRX Position: Q2 2021 in Review

Raymond James & Associates sold out of VolitionRx Ltd (VNRX) in Q2 2021, closing a stake of 1,556 shares — an estimated $118K sold.

Raymond James & Associates first reported a position in VNRX in Q4 2020 and held it in 2 quarters. The position peaked at $118K in Q1 2021. 46 funds tracked by Wall St. Rank hold VNRX as of Q2 2021.

  • Raymond James & Associates reported no remaining VolitionRx Ltd position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 1,556 VolitionRx Ltd shares in Q2 2021, an estimated $118K.
  • Raymond James & Associates first reported a position in VolitionRx Ltd in Q4 2020 and held it in 2 quarters.
  • Raymond James & Associates's VolitionRx Ltd position peaked at $118K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held VolitionRx Ltd as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.